Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

925 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vimentin-positive invasive breast carcinoma of no special type: A breast carcinoma with lethal biological characteristics.
Ichinose Y, Hasebe T, Hirasaki M, Sakakibara A, Yokogawa H, Nukui A, Hiratsuka M, Fujimoto A, Iso C, Wakui N, Shibasaki S, Kamada K, Suzuki N, Kamakura Y, Yasuda M, Aya A, Shimada H, Matsuura K, Ishiguro H, Osaki A, Saeki T. Ichinose Y, et al. Among authors: ishiguro h. Pathol Int. 2023 Sep;73(9):413-433. doi: 10.1111/pin.13350. Epub 2023 Jun 28. Pathol Int. 2023. PMID: 37378453
Significance of the comprehensive geriatric assessment in the administration of chemotherapy to older adults with cancer: Recommendations by the Japanese Geriatric Oncology Guideline Committee.
Ninomiya K, Inoue D, Sugimoto K, Tanaka C, Murofushi K, Okuyama T, Watanuki S, Imamura CK, Sakai D, Sakurai N, Watanabe K, Tamura K, Saeki T, Ishiguro H. Ninomiya K, et al. Among authors: ishiguro h. J Geriatr Oncol. 2023 Jun;14(5):101485. doi: 10.1016/j.jgo.2023.101485. Epub 2023 Apr 14. J Geriatr Oncol. 2023. PMID: 37062639 Free article. Review.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M. Takada M, et al. Among authors: ishiguro h. Breast Cancer Res Treat. 2023 Dec;202(3):485-496. doi: 10.1007/s10549-023-07099-4. Epub 2023 Sep 7. Breast Cancer Res Treat. 2023. PMID: 37676450 Free PMC article.
Clinicopathological prognostic characteristics and long‑term outcomes of patients with breast cancer and collagen disorder in comparison to those without collagen disorder.
Matsuura K, Osaki A, Ichinose Y, Fujimoto A, Sakakibara A, Nukui A, Yokogawa H, Shimada H, Asano A, Ohara M, Ishiguro H, Takahashi T, Saeki T. Matsuura K, et al. Among authors: ishiguro h. Oncol Lett. 2023 Sep 29;26(5):495. doi: 10.3892/ol.2023.14082. eCollection 2023 Nov. Oncol Lett. 2023. PMID: 37854859 Free PMC article.
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S. Iwamoto T, et al. Among authors: ishiguro h. Breast Cancer Res Treat. 2024 Jan;203(2):225-234. doi: 10.1007/s10549-023-07144-2. Epub 2023 Oct 25. Breast Cancer Res Treat. 2024. PMID: 37875670
Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).
Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Kobayashi T, Katagiri Y, Kitada M, Tomioka N, Miyoshi Y, Shigematsu H, Miyashita M, Ishiguro H, Masuda N, Saji S. Iwamoto T, et al. Among authors: ishiguro h. Breast Cancer Res Treat. 2024 Nov;208(2):253-262. doi: 10.1007/s10549-024-07414-7. Epub 2024 Jun 26. Breast Cancer Res Treat. 2024. PMID: 38922548
Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy triple negative breast cancer tumors.
Nishimura T, Velaga R, Masuda N, Kawaguchi K, Kawaguchi S, Takada M, Maeshima Y, Tanaka S, Kikawa Y, Kadoya T, Bando H, Nakamura R, Yamamoto Y, Ueno T, Yasojima H, Ishiguro H, Morita S, Ohno S, Haga H, Matsuda F, Ogawa S, Toi M. Nishimura T, et al. Among authors: ishiguro h. Cancer Sci. 2024 Dec;115(12):3928-3942. doi: 10.1111/cas.16339. Epub 2024 Oct 7. Cancer Sci. 2024. PMID: 39375938 Free PMC article.
Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: propensity score matching and inverse probability of treatment weighting analysis.
Yamaguchi A, Kawaguchi K, Kawanishi K, Maeshima Y, Nakakura A, Kataoka TR, Takahara S, Nakagawa S, Yonezawa A, Takada M, Kawashima M, Kawaguchi-Sakita N, Kotake T, Suzuki E, Shimizu H, Torii M, Morita S, Ishiguro H, Toi M. Yamaguchi A, et al. Among authors: ishiguro h. Breast Cancer Res Treat. 2024 Apr;204(2):261-275. doi: 10.1007/s10549-023-07163-z. Epub 2023 Dec 21. Breast Cancer Res Treat. 2024. PMID: 38123790 Free PMC article.
925 results